Assist. Prof. Dr. Yuji Habu | Gynecology – Assistant Professor at Department of Obstetrics and Gynecology, Chiba University Hospital, Japan
Dr. Yuji Habu is an accomplished academic and clinical researcher specializing in Obstetrics and Gynecology. With a robust background in both medical practice and research, he is currently an Assistant Professor in the Department of Obstetrics and Gynecology at Chiba University Hospital. His work focuses on women’s health, particularly in the areas of gynecologic oncology, early detection, and cancer treatment innovations. Known for his interdisciplinary approach and commitment to improving patient outcomes, Dr. Habu has become a leading figure in his field. He has significantly contributed to numerous studies, offering insights that shape both clinical practices and academic knowledge globally.
Profile:
Education:
Dr. Habu’s educational journey began with his medical studies at Kanazawa University, where he earned his Medical Degree (MD) in 2008. He pursued his doctoral studies at Chiba University, earning a PhD in 2022 from the Graduate School of Medical and Pharmaceutical Sciences. His academic excellence has laid a solid foundation for his clinical career and research endeavors. The comprehensive education provided him with both the theoretical and practical knowledge necessary to address complex medical challenges, particularly in the realms of gynecologic cancers and women’s reproductive health.
Experience:
Dr. Habu’s career spans across various roles, beginning with his initial work as a Resident in Internal Medicine at Yokosuka General Hospital in 2008. He later transitioned into Obstetrics and Gynecology, working in multiple hospitals, including Chiba University Hospital and Kimitsu Chuo Hospital. His roles as a Senior Resident and Clinical Staff Physician have equipped him with the hands-on experience needed to complement his research. In 2019, he became an Assistant Professor at Chiba University Hospital, where he currently leads both clinical and research initiatives. His diverse experience across multiple institutions has enabled him to develop a well-rounded perspective on patient care and medical research.
Research Interests:
Dr. Habu’s research interests are primarily centered around gynecologic oncology, focusing on the early detection, treatment, and management of cancers such as cervical, endometrial, and ovarian cancers. He is particularly interested in innovative diagnostic techniques, such as the use of sentinel lymph node mapping in cancer surgeries, and exploring new therapeutic approaches. His work has also extended to examining the long-term outcomes of fertility-sparing treatments for endometrial hyperplasia and cancer. Dr. Habu has contributed to research on using advanced imaging techniques like diffusion-weighted MRI to predict prognosis in uterine cervical cancer patients, as well as evaluating new treatment regimens in ovarian cancer survivors.
Awards and Recognition:
Dr. Habu has been recognized for his significant contributions to medical research and patient care, particularly in the fields of obstetrics and gynecology. His innovative research in cancer treatments and diagnostic techniques has earned him multiple accolades. As a highly regarded specialist and leader in his field, he has received national recognition through board certifications from various prestigious societies, including the Japanese Society of Internal Medicine and the Japan Society of Obstetrics and Gynecology. His ongoing work continues to pave the way for advances in gynecologic oncology.
Publications:
Dr. Habu has authored a number of high-impact research articles that have contributed to the advancement of gynecologic oncology. Here are a few key publications:
-
Habu Y, Usui H, Hanawa S, et al. Evaluation of the usefulness of sentinel lymph node mapping using indocyanine green in patients with cervical and endometrial cancers: A single-center prospective exploratory study. J Obstet Gynaecol Res. 2025;51(2):e16254. 馃搫
Cited by multiple articles in gynecological oncology, emphasizing innovative cancer staging techniques.
-
Matsuoka A, Tate S, Nishikimi K, et al. Therapy-related myeloid neoplasms after treatment for ovarian cancer: A retrospective single-center case series. J Obstet Gynaecol Res. 2024;50:1148-54. 馃搫
This research has been cited in studies exploring long-term effects of cancer therapies on survivors.
-
Okonogi N, Murata K, Yamada S, et al. A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results. Int J Mol Sci. 2023;24(13):10565. 馃搫
Highly cited in immunotherapy and radiotherapy research, showing promise in advanced cervical cancer treatment.
-
Takada A, Yokota H, Nemoto MW, et al. Prognosis prediction of uterine cervical cancer using changes in histogram and texture features of apparent diffusion coefficient during definitive chemoradiotherapy. PLoS One. 2023;18:e0282710. 馃搫
Widely referenced in research on imaging biomarkers for predicting cancer prognosis.
-
Tamura M, Uzawa A, Kitayama Y, et al. Multiple cerebral infarctions complicating deep vein thrombosis associated with uterine adenomyosis: A case report and literature review. Cureus. 2022;14:e28061. 馃搫
Cited by multiple studies examining rare complications in gynecologic diseases.
-
Mitsuhashi A, Ishikawa H, Habu Y, et al. The effect of steep head-down tilt on respiratory status in endometrial cancer patients with obesity during robot-assisted hysterectomy. Gynecol Oncol Rep. 2022;41:101014. 馃搫
Cited in surgical oncology literature on improving surgical outcomes in high-risk patients.
-
Habu Y, Mitsuhashi A, Hanawa S, et al. High prevalence of pulmonary embolism prior to cancer therapies in patients with ovarian and endometrial cancers detected by contrast-enhanced CT using D-dimer as an index. J Surg Oncol. 2021;124:106-14. 馃搫
This study has influenced preoperative protocols for gynecologic cancer patients.
Conclusion:
Dr. Yuji Habu is an exceptional researcher whose work in gynecologic oncology has had a profound impact on clinical practices and patient care. His research has contributed significantly to improving cancer treatments, particularly in the areas of diagnosis, prevention, and post-treatment management. With a consistent track record of high-quality publications and a dedication to advancing women’s health, Dr. Habu is a deserving candidate for the “Best Researcher Award.” His contributions continue to push the boundaries of medical knowledge and will undoubtedly shape the future of gynecological cancer treatment.